Shares of OvaScience Inc OVAS soared over 35 percent Thursday following its announcement on Wednesday that it achieved its 2014 corporate goals.
The company is advancing the AUGMENTSM, OvaPrimeSM and OvaTureSM treatments for patients in need of new fertility treatment options.
The company indicated that its OvaPrime Treatment will be introduced into select international IVF Clinics by the end of 2015.
Amid the positive news, Wedbush Securities initiated coverage on OvaScience with a Outperform rating and a $47.00 price target.
OvaScience Inc recently traded at $47.40, up 35.58 percent.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
